Axcella Revenue and Competitors
Estimated Revenue & Valuation
- Axcella's estimated annual revenue is currently $13.5M per year.
- Axcella's estimated revenue per employee is $499,444
- Axcella's total funding is $151.3M.
Employee Data
- Axcella has 27 Employees.
- Axcella grew their employee count by -64% last year.
Axcella's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Clinical Development | Reveal Email/Phone |
2 | Senior Manager Payroll & Stock Plan Admin | Reveal Email/Phone |
3 | Senior Scientist | Reveal Email/Phone |
4 | Senior Research Associate, Computational Biology | Reveal Email/Phone |
Axcella Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Axcella?
Axcella is designing and developing novel endogenous metabolic modulator compositions to safely reprogram metabolic dysregulation. We are transforming the discovery and development of traditional drug and consumer health candidates from concept to clinical stages, by leveraging our deep understanding of human biology. Our novel approach rapidly gains unprecedented information in a capital efficient manner. Our platform has already produced a rich pipeline of product candidates in programs targeting liver, muscle, and CNS. Axcella Health was founded by Flagship Pioneering.
keywords:Biotechnology,Healthcare
$151.3M
Total Funding
27
Number of Employees
$13.5M
Revenue (est)
-64%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Axcella News
Axcella Health Inc gets a 41 rank in the Biotechnology industry. Biotechnology is number 69 out of 148 industries. Overall Score - 39. AXLA has...
Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic...
Axcella Health Inc. (NASDAQ:AXLA) Q4 2021 Earnings Conference Call March 30, 2022 8:30 AM ET. Company Participants.
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.7M | 27 | N/A | N/A |
#2 | $1.9M | 27 | -7% | $5M |
#3 | $4.2M | 27 | 4% | N/A |
#4 | $3.5M | 27 | 8% | N/A |
#5 | $4.2M | 27 | -53% | N/A |